CNS Mobile Logo

Publications & Presentations

Publications and Presentations

  • (0)
  • (1)
  • (2)
  • (1)
  • (4)
  • (0)
  • (0)
11 August, 2023
2023 SNO/ASCO CNS Cancer Conference

A Randomized, Controlled Trial Of Berbubicin, A Novel Topoisomerase II Inhibitor, After First-Line Therapy For Glioblastoma Multiforme (GBM): Updated Results

By: Z. Muzyczenko (1), S. Silberman (1), S. Hsu (2), D. Picker (1) (1) CNS Pharmaceuticals, Houston, TX, (2) Memorial Hermann Texas Medical Center, Houston, TX,
Berubicin (Recurrent GBM)
18 November, 2022
Society for Neuro-Oncology Annual Meeting 2022

A Randomized, Controlled Trial Of Berbubicin, A Novel Topoisomerase II Inhibitor, After First-Line Therapy For Glioblastoma Multiforme (GBM): Preliminary Results

By: S. Silberman (1), S. Hsu (2), Z. Muzyczenko (1), D. Picker (1), S. Bisdas (3), O. Kubassova (4), J. O‘Lynn (4), W. Priebe (5) (1) CNS Pharmaceuticals, Houston, TX, (2) Memorial Hermann Texas Medical Center, Houston, TX, (3) UCL Hospitals NHS Trust, London, UK, (4) IAG, Image Analysis Group, London, UK, (5) MD Anderson Cancer Center, Houston, TX
Berubicin (Recurrent GBM)
05 June, 2022
American Society of Clinical Oncology Annual Meeting 2022

Design And Initiation Of An Adaptive, Randomized, Controlled Study Of Berubicin, A Topoisomerase II Poison That Crosses The Blood-Brain Barrier For The Treatment Of Recurrent Glioblastoma Multiforme (GBM)

By: S. Silberman (1), S. Hsu (2), Z. Muzyczenko (1), D. Picker (1), W. Priebe (3) (1) CNS Pharmaceuticals, Houston, TX, (2) Memorial Hermann Texas Medical Center, Houston, TX, (3) The University of Texas M. D. Anderson Cancer Center, Houston, TX
Berubicin (Recurrent GBM)
19 November, 2021
Society for Neuro-Oncology Annual Meeting 2021

Design and Initiation Of Pivotal Studies For Berubicin, A Novel, Potent Topoisomerase II Poison For The Treatment Of Recurrent Glioblastoma Multiforme (GBM)

By: S. Silberman (1), S. Hsu (2), Z. Muczyczenko (1), D. Picker (1), M. Sipowicz (3), E. Żak (3), A. Buczyńska (3), M. Olejniczak (3), W. Priebe (4) (1) CNS Pharmaceuticals, Houston, TX, (2) Memorial Hermann Texas Medical Center, Houston, TX, (3) WPD Pharmaceuticals, Warszawa, Poland, (4) The University of Texas M. D. Anderson Cancer Center, Houston, TX
Berubicin (Recurrent GBM)
There are no publications that match the selected filters.